Pt Bundamedik Tbk · IDX:BMHS
Pt Bundamedik Tbk — 9M22 Earnings Presentation
27 slides from Pt Bundamedik Tbk's earnings presentation, November 2022
Slide 1: PT Bundamedik Tbk – Analyst Meeting 9M22 Results
PT Bundamedik Tbk Analyst Meeting – 9M22 Results Nov 2022 Disclaimer: Presentation are intended for educational purposes only and do not replace independent professional judgement. Statements of fact and opinions are those of the participants individually and, unless expressly stated to the contrary
Slide 2: Leading Provider in Specialized Healthcare Services since 1973
Leading Provider in Specialized Healthcare Services since 1973
Slide 3: Bundamedik Tbk (BMHS) Ecosystem
Bundamedik Tbk (BMHS) Ecosystem Expanding Presence RSIA Az Zahra 9 HOSPITALS + 3 CLINICS Women & Children Hospitals 10 IVF CLINICS PADANG PONTIANAK BATAM 46 LABORATORIES Bunda Hospitals PALEMBANG MAKASSAR CLINICS NETWORK 200++ (KLINIK PINTAR) YOGYAKARTA 126 FERTILITY CLINICS NETWORK (KFI) Jakarta De
Slide 4: 9M22 Key Highlights
9M22 Key Highlights Across all metrics, surpassed Pre-Covid level EBITDA Margin Normalized to Pre-covid Level +21% # of Outpatients +73% +108% # of IP Days 23% 24% +48% # of Surgeries +220% # of Lab Tests EBITDA margin EBITDA margin Net revenue at Pre-COVID Level Excluding newly acquired hospitals D
Slide 5: 9M22 Results
9M22 Results Expanding 9M22 Results Presence Strategic Strengthening Partnership Our Core
Slide 6: Financial & Operational Performance
Financial & Operational Performance Core Businesses Continues to Improve In Rp B, unless otherwise specified HIGHLIGHTS )* )* OF CONSOLIDATED RESULT 2Q22 3Q22 QoQ (%) 9M22 9M21 YoY (%) HIGHLIGHTS HIGHLIGHTS OPERATIONALS 1 # Outpatient 109.003 130.258 19% 347.094 284.995 22% 1 Hospitals: operating me
Slide 7: Hospitals Volume
Hospitals Volume # OUTPATIENTS # IP ADMISSION +55% +22% +1% -8% 383.1 359.6 390.5 24.8 347.1 22.1 288.0 270.8 285.0 19.6 18.8 +21% 16.8 15.1 16.0 +48% 2019 2020 2021 9M19 9M20 9M21 9M22 2019 2020 2021 9M19 9M20 9M21 9M22 # IP DAYS # SURGERIES +18% +43% +7% +21% 99.1 7.5 7.7 7.9 92.2 83.8 6.8 62.8 65
Slide 8: Financial Performance
Financial Performance Consolidated NET REVENUE EBITDA (Rp B) (Rp B,% Margin) +21% +58% 1.530 33% 30% +39% +20% 27% 25% 1.185 23% 460 23% 23% 1.083 394 887 795 +73% 627 629 250 224 185 169 +76% 142 2019 2020 2021 9M19 9M20 9M21 9M22 2019 2020 2021 9M19 9M20 9M21 9M22
Slide 9: Balance Sheet
Balance Sheet Remains robust CASH VS DEBT NET DEBT-TO-EBITDA (Rp B) (x) Net 430 417 -135 204 Debt 794 834 2.2x 625 613 629 518 490 0.7x 100 -0.6x -0.4x 2019 2020 2021 Sep-22 2019 2020 2021 LTM Sep-22 AR Days WORKING CAPITAL DAYS Inventory Days 58 AP Days 53 50 50 29 33 26 19 17 14 9 10 2019 2020 202
Slide 10: Higher contributions from core business
Higher contributions from core business offset declining Covid-related businesses NON-COVID REVENUE QUARTERLY REVENUE 14% Covid (Rp B) *) Non Covid DELTA WAVE SECOND WAVE Rp 981 B Rp 1,116 B 9M21 9M22 FIRST WAVE OMICRON WAVE 451 452 389 379 393 420 388 *) 14 23 8 348 118 116 334 107 33 18 +23% 262 5
Slide 11: IVF Cycles: growth momentum continues
IVF Cycles: growth momentum continues Growth diversification outside Jakarta # OF IVF CYCLES (‘00) +2% 42.5 43.2 6.2 5.8 5.8 5.6 5.5 5.2 5.3 5.1 4.9 4.9 4.8 4.9 4.8 4.9 4.7 4.7 4.5 4.2 3.9 3.7 8% 3.2 55% 62% 14.3 15.4 Jakarta Outside 45% Jakarta 38% 9M21 9M22 2Q22 3Q22 Jan-21 Feb-21 Apr-21 Jan-22 Fe
Slide 12: Diagnos: Growing Non-Covid Tests
Diagnos : Growing Non-Covid Tests Offsetting rapidly declining Covid Tests # OF TESTS (‘000) +13% Covid Non Covid 104 649 575 84 85 83 75 78 76 70 67 64 63 64 62 61 60 54 51 50 55 53 55 +25% +24% 9M22 Non Covid 214 Test YoY 171 9M21 9M22 2Q22 3Q22 Jan-21 Mar-21 Apr-21 Jan-22 Mar-22 Apr-22 Feb-21 Jun
Slide 13: Expanding Presence
Expanding Presence Expanding Strong FY 2021 9M22 Results Presence Results Strategic Strengthening Partnership Our Core
Slide 14: Expanding Presence: Diagnos Labs and Hospital Beds
Expanding Presence # OF DIAGNOS LABS # OF HOSPITAL BEDS Covid 46 Non Covid 639 656 48 48 506 34 478 441 29 414 387 133 168 340 336 196 181 193 591 608 120 15 345 338 7 216 221 245 206 3 4Q19 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 2018 2019 2020 2021 9M21 9M22
Slide 15: Expanding Presence: New Hospitals
Expanding Presence New Hospitals RSIA Azzahra Palembang RSJP Paramartha Bandung RSU Citra Harapan Bekasi RS Bunda Morula Surabaya Bunda Denpasar RS Vida Bekasi Bunda Denpasar is on progress to be a Mother and RS Vida Bekasi on construction progress Children Hospital
Slide 16: Newly acquired hospitals
Newly acquired hospitals Narrowing losses, expect contribution in 2023 Financial Disclosure 9M222) 581 147 29 1 2 3 4 -5 Revenue EBITDA Existing Hospitals New Hospitals 1) New hospitals are defined as hospitals built or acquired within the last 24 months 2) Net Revenue and EBITDA Core Business (excl
Slide 17: Strengthening Our Core
Strengthening Our Core Expanding 9M22 Results Presence Strategic Strengthening Partnership Our Core
Slide 18: Employing Advanced Technology
Employing Advanced Technology Higher Success Rate Higher Pregnancy Higher Pregnancy Success Rate Success Rate 68% 46% Morula is the first to offer PGT-A test which led to >50% success rate vs. non-PGT-A1) 43% 27% PGT-A is the latest leading technology for chromosome screening in embryos offered by M
Slide 19: Comprehensive Facility and Supporting Services
Comprehensive Facility and Supporting Services COMPREHENSIVE NICU PICU BUNDA HEART CENTRE UROLOGY CENTRE CATH LAB & DSA ADVANCE ROBOTIC MINIMAL ONCOLOGY CENTRE INVASIVE SURGERY
Slide 20: Our New Booking Platform
Our New Booking Platform onebunda.com 20
Slide 21: Environmental, Social, & Governance Updates
Environmental, Social, & Governance Updates SKILLS AND CAPABILITIES ENHANCEMENT THROUGH PARTNERSHIP PROGRAM WITH TOP MEDICAL SCHOOL IN INDONESIA New partnership in 2022 CSR BMHS x BPJS TK BMHS Scholarship x FKUI International Research and education partnership as part of medical professionals attrac
Slide 22: Ensuring Standardised Quality Process
Ensuring Standardised Quality Process
Slide 23: Strategic Partnership
Strategic Partnership Expanding 9M22 Results Presence Strong FY 2021 Results Strategic Strengthening Partnership Our Core
Slide 24: Enhancing Our Ecosystem: Klinik Fertilitas Indonesia (KFI)
Enhancing Our Ecosystem: Klinik Fertilitas Indonesia (KFI) Rising referral and conversion to IVF Treatment Morula strong presence through extensive KFI networks 126 KFI Partnership with local Obgyn clinics Clinics # PATIENTS REFERRED TO MORULA (x) • Efficient way to scale up Morula’s business +79% C
Slide 25: 2023 Key Focus Area
2023 Key Focus Area 1 Improve the performance of our newly acquired hospitals 2 Continue with cost efficiency initiatives to improve profitability Optimize productivity and performance of our network: KFI (satellite clinics for 3 Morula) and Diagnos lab outlets Enhance our competitive edge through b
Slide 26: Key Take Away
Key Take Away Integrated Healthcare Ecosystem – well positioned to capture rapid growth in Indonesia Healthcare sector Strong Core Offerings – leader in Women & Children and IVF, developing other engines of growth Proven Track Record with strong and professional management team Robust Financials and
Slide 27: Thank You
THANK YOU Disclaimer: Presentation are intended for educational purposes only and do not replace independent professional judgement. Statements of fact and opinions are those of the participants individually and, unless expressly stated to the contrary. Specific data in this presentation was obtaine